{"id":1140,"date":"2013-05-01T12:07:00","date_gmt":"2013-05-01T10:07:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/diabetes-mellitus-typ-2-glp-1-basierte-therapien-pankreatitis-und-pankreas-neoplasien"},"modified":"2013-05-01T12:07:00","modified_gmt":"2013-05-01T10:07:00","slug":"diabetes-mellitus-typ-2-glp-1-basierte-therapien-pankreatitis-und-pankreas-neoplasien","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/diabetes-mellitus-typ-2-glp-1-basierte-therapien-pankreatitis-und-pankreas-neoplasien","title":{"rendered":"Diabetes mellitus Typ 2: GLP-1-basierte Therapien, Pankreatitis und Pankreas-Neoplasien"},"content":{"rendered":"<p>Im August 2011 haben wir ausf\u00fchrlich \u00fcber den damaligen Stand der Kenntnisse zu unerw\u00fcnschten Arzneimittelwirkungen am Pankreas von Glucagon-like peptide-1(GLP1)-Analoga (Exenatid, Liraglutid) und von Dipeptidyl-Peptidase-Typ-IV-Inhibitoren (sog. Gliptinen) berichtet (1). Damals hatten Elashoff et al. aus Los Angeles \u00fcber eine etwa 10-fach erh\u00f6hte Melderate von Pankreatitiden bei Anwendern von Exenatid oder Sitagliptin, verglichen mit Anwendern anderer [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im August 2011 haben wir ausf\u00fchrlich \u00fcber den damaligen Stand der Kenntnisse zu unerw\u00fcnschten Arzneimittelwirkungen am Pankreas von Glucagon-like peptide-1(GLP1)-Analoga (Exenatid, Liraglutid) und von Dipeptidyl-Peptidase-Typ-IV-Inhibitoren (sog. Gliptinen) berichtet (1). Damals hatten Elashoff et al. aus Los Angeles \u00fcber eine etwa 10-fach erh\u00f6hte Melderate von Pankreatitiden bei Anwendern von Exenatid oder Sitagliptin, verglichen mit Anwendern anderer [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[155,2822,1310,1309,2291,2823,277,2824,2598,1441],"class_list":["post-1140","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-diabetes-mellitus-typ-2","tag-exenatid","tag-gliptine","tag-inkretinmimetika","tag-linagliptin","tag-liraglutid","tag-pankreaskarzinom","tag-pankreasneoplasien","tag-pankreatitis","tag-sitagliptin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1140","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1140"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1140\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1140"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1140"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}